Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-11
2008-07-29
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07405208
ABSTRACT:
The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
REFERENCES:
patent: 3595955 (1971-07-01), De Boer et al.
patent: 3987035 (1976-10-01), Rinehart, Jr. et al.
patent: 4075339 (1978-02-01), Rinehart, Jr. et al.
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 4421687 (1983-12-01), Hasegawa et al.
patent: 4421688 (1983-12-01), Muroi et al.
patent: 4540517 (1985-09-01), Tanida et al.
patent: 5387584 (1995-02-01), Schnur
patent: 5932566 (1999-08-01), Schnur et al.
patent: 5968921 (1999-10-01), Gold
patent: 6245759 (2001-06-01), Bilodeau et al.
patent: 6306874 (2001-10-01), Fraley et al.
patent: 6313138 (2001-11-01), Fraley et al.
patent: 6890917 (2005-05-01), Snader et al.
patent: 6946456 (2005-09-01), Rosen et al.
patent: 2002/0045570 (2002-04-01), Rosen et al.
patent: 2004/0110662 (2004-06-01), Rosen et al.
patent: 2004/0266746 (2004-12-01), Rosen et al.
patent: 2005/0020534 (2005-01-01), Johnson, Jr.
patent: 2005/0020556 (2005-01-01), Johnson, Jr.
patent: 2005/0020557 (2005-01-01), Johnson, Jr.
patent: 2005/0020558 (2005-01-01), Johnson, Jr.
patent: 2005/0026893 (2005-02-01), Johnson, Jr.
patent: 2005/0049263 (2005-03-01), Kasibhatla et al.
patent: 2005/0054589 (2005-03-01), Johnson, Jr.
patent: 2005/0054625 (2005-03-01), Johnson, Jr.
patent: 2005/0203174 (2005-09-01), Santi et al.
patent: 2005/0256183 (2005-11-01), Kasibhatla et al.
patent: 2006/0079493 (2006-04-01), Fritz et al.
patent: 2006/0252740 (2006-11-01), Johnson, Jr.
patent: 2007/0142346 (2007-06-01), Johnson, Jr.
patent: 0 919 244 (1999-06-01), None
patent: 55-111419 (1980-08-01), None
patent: 55-111470 (1980-08-01), None
patent: 56-100766 (1981-08-01), None
patent: 57-163369 (1982-10-01), None
patent: 63-218620 (1988-09-01), None
patent: 4-46120 (1992-02-01), None
patent: WO-93/14215 (1993-07-01), None
patent: WO-98/51702 (1998-11-01), None
patent: WO-00/03737 (2000-01-01), None
patent: WO-00/37050 (2000-06-01), None
patent: WO-01/26693 (2001-04-01), None
patent: WO 01/32155 (2001-10-01), None
patent: WO-02/09696 (2002-02-01), None
patent: WO-02/36171 (2002-05-01), None
patent: WO-02/36574 (2002-05-01), None
patent: WO-02/079167 (2002-10-01), None
patent: WO-02/087497 (2002-11-01), None
patent: WO-03/026571 (2003-04-01), None
patent: WO-03/050295 (2003-06-01), None
patent: WO-03/066005 (2003-08-01), None
patent: WO-03/082266 (2003-10-01), None
patent: WO-03/089006 (2003-10-01), None
Anderson, Targeting host-tumour interactions in myeloma therapies, Teaching Lectures (2003) S6, no. 11.
Blagoskylonny et al., Leukemia (2001) 15:1537-1543.
Chem. Abstracts 130:291581, van der Bosch et al. (1999), assession No. 1999:254052 CAPLUS.
Grant and Roberts, Drug Resistance Updates (2003) 6:15-26.
Hurst et al., Clinical Cancer Research (1999) (supplemenet) 5(293):3788s.
Jia et al., Blood (2003) 102(5):1824-1832.
Liao et al., Acta Pharmaceutica Sinica (2001) 36(8):569-575.
Münster et al., Clinical Cancer Research (2001) 7:2228-2236.
Neckers and Neckers, Expert Opin. Emerging Drugs (2002) 7(2):277-288.
Nguyen et al., Ann. Thorac. Surg. (2001) 72:371-379.
Nguyen et al., J. Thorac. Cardiovasc. Surg. (1999) 118:908-915.
Rahmani et al., Cancer Research (2003) 63:8420-8427.
Rakitina et al., Cancer Research (2003) 63:8600-8605.
Russell et al., Clinical Cancer Research (2003) 9:3749-3755.
Sausville, Clinical Cancer Research (2001) 7:2155-2158.
Solit et al., Cancer Research (2003) 63:2139-2144.
Vasilevskaya et al., Cancer Research (2003) 63:3241-3246.
CITRI et al., EMBO Journal (2002) 21:2407-2417.
International Search Report for PCT/US02/24891, mailed on Nov. 28, 2003, 4 pages.
Kamal et al.; Nature (2003) 425:407-410.
Munster et al., Clinical Cancer Research (2001) 7:2228-2236.
Neckers and Lee, Nature (2003) 425:357-359.
Schnur et al., J. Med. Chem. (1995) 38:3806-3812.
Schnur et al., J. Med. Chem. (1995) 38:3813-3820.
Birgegard, European Journal of Cancer Supplements (2003) 1(5):S6.
U.S. Appl. No. 10/856,342, filed May 27, 2004.
U.S. Appl. No. 10/856,344, filed May 27, 2004.
U.S. Appl. No. 10/856,696, filed May 27, 2004.
U.S. Appl. No. 10/856,703, filed May 27, 2004.
U.S. Appl. No. 10/856,742, filed May 27, 2004.
U.S. Appl. No. 10/857,166, filed May 27, 2004.
U.S. Appl. No. 10/857,605, filed May 27, 2004.
Feng Li
Hutchinson C. Richard
Johnson Robert
Myles David C.
Santi Daniel
Kosan Biosciences, Inc.
Kwon Brian
Morrison & Foerster / LLP
LandOfFree
Benzoquinone ansamycins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoquinone ansamycins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoquinone ansamycins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3969159